Healthcare Overview: The Kuwaiti Market in 2026 — Vision...

Kuwait's healthcare system stands at a paradox: one of the highest per-capita health expenditures in the world — $2,292 in 2023, more than five times the global median — yet a market that has historically underperformed its GCC peers in infrastructure modernization, digital health adoption, and pharmaceutical self-sufficiency. In 2026, that is changing.

With a $10 billion healthcare budget, plans for 10 new hospitals, the country's first major pharmaceutical factory, and the Middle East's first public-private healthcare partnership, Kuwait is translating financial muscle into structural transformation under Vision 2035.

The Numbers: A Well-Funded Market

Kuwait's pharmaceutical market is projected to reach US$924 million in 2025, growing at a CAGR of 5.1% through 2029. The broader healthcare market — including hospital services valued at $6.4 billion — is one of the most generously funded in the region. Healthcare commands 11% of Kuwait's national budget, with $10 billion allocated for 2024/2025.

Oncology drugs lead the pharmaceutical market at a projected $169 million in 2025, followed by anti-diabetes, anti-rheumatic, vaccines, and dermatological therapies. Growth is driven by an aging population, rising chronic disease prevalence, and increasing demand for specialized medications.

The outpatient care model dominates, with Kuwaitis increasingly preferring ambulatory care settings. Private health expenditure is growing faster than public spending as the government seeks to reduce fiscal burden amid oil revenue volatility.

Vision 2035: International Partnerships at Scale

Since launching a comprehensive healthcare transformation in October 2023, Kuwait's Ministry of Health has secured a series of high-profile international partnerships designed to elevate clinical standards and reduce the country's reliance on overseas medical referrals:

• Great Ormond Street Hospital (London) — March 2024, pediatric care excellence
• Gustave Roussy (France) — February 2025, oncology and cancer research
• UAE — June 2025, strategic healthcare cooperation
• Bahrain — October 2025, cross-border clinical collaboration
• United Kingdom — October 2025, broad healthcare partnership

These agreements focus on knowledge transfer, professional training, and clinical cooperation — building the institutional capacity that Kuwait has historically sourced abroad. The strategy is clear: instead of sending patients overseas for specialized treatment, bring global expertise to Kuwait.

Hospital Infrastructure: 10 New Facilities

The government has committed $608 million for healthcare infrastructure, with plans to build and expand 10 hospitals over the next five years. Two flagship projects define the ambition:

Sabah Al-Ahmad Medical City and Mutlaa Medical City — each featuring a 500-bed hospital with supporting dental clinics, physiotherapy centers, dialysis units, and staff housing. In October 2025, the Cabinet directed the Ministry of Health to prepare preliminary plans for both cities in accordance with international standards.

A broader facilities modernization program covering hospital maintenance, construction, and expansion across Kuwait City is targeting completion by Q1 2027. Together, these projects represent the largest hospital infrastructure investment Kuwait has undertaken in a generation.

Pharma Manufacturing: The Al-Shifa Milestone

In a pivotal development for Kuwait's pharmaceutical independence, the Al-Shifa Pharmaceutical Factory — owned by the Kuwait-Saudi Pharmaceutical Industries Company — is scheduled to begin operations in March 2026.

Health Minister Dr. Ahmad Al-Awadhi has positioned local pharmaceutical production as essential to Kuwait's healthcare resilience and medical self-sufficiency. Unlike neighbors Saudi Arabia, UAE, and Egypt, Kuwait has historically been almost entirely dependent on pharmaceutical imports. Al-Shifa changes that equation.

The pharmaceutical contract manufacturing market in Kuwait is already valued at $370 million, driven by rising demand for generics and government support for local production. With the regulatory environment being shaped to encourage domestic manufacturing and the KDFA aligning registration processes with international CTD standards, the foundation for a local pharma ecosystem is taking shape.

DHAMAN: The Middle East's First Healthcare PPP

Established in 2014 under an Amiri Directive, DHAMAN is the first public-private partnership healthcare organization in the Middle East. With over 7,000 employees, it operates an integrated system spanning medical insurance programs, primary healthcare centers, and hospitals.

Its shareholding structure reflects Kuwait's hybrid approach: Kuwait Investment Authority and Public Institution for Social Security (24%), a private sector strategic partner (26%), and Kuwaiti citizens via IPO (50%). DHAMAN demonstrates that large-scale healthcare PPPs are viable in the GCC — a model other countries in the region are watching closely.

As private health expenditure grows faster than public spending, DHAMAN's role in absorbing demand and delivering care outside the public hospital system becomes increasingly strategic.

Digital Health: Catching Up to the GCC

Kuwait's digital health transformation lags behind UAE and Saudi Arabia, but investment is accelerating. The government has allocated $56 million for digital transformation in the 2024/2025 budget, with the centerpiece being a Hospital Information Exchange (HIE) platform to transition 28 public hospitals from paper-based to digital systems.

Currently, Al Amiri Hospital is the only public facility with a complete digital healthcare infrastructure. The remaining 27 hospitals and healthcare centers are planned to follow the same digitalization model — a significant undertaking that will form the backbone of Kuwait's health data infrastructure.

The gap presents both a challenge and an opportunity. For health tech companies and digital health vendors, Kuwait represents a greenfield market with government funding, clear demand, and a population that is among the most digitally connected in the region.

Challenges Ahead

• Import dependency: Kuwait remains almost entirely reliant on pharmaceutical imports; Al-Shifa is a first step, but building a diversified local manufacturing base will take years.
• Digital health lag: With only 1 of 28 public hospitals fully digitized, the transition timeline is ambitious and execution-dependent.
• Workforce constraints: Scaling 10 new hospitals requires a proportional expansion of physicians, nurses, and specialists — a challenge across the GCC.
• Oil revenue dependency: Healthcare budgets are directly tied to oil prices; sustained investment requires fiscal diversification under Vision 2035.
• Overseas referrals: Despite partnership efforts, reducing the volume and cost of patients seeking treatment abroad remains a long-term structural challenge.

What This Means for Patients and Industry

For patients, Kuwait's investment trajectory is reshaping access. Two new medical cities, 10 hospital expansions, and international partnerships with institutions like Great Ormond Street and Gustave Roussy promise higher-quality care closer to home — reducing the need for costly overseas referrals.

For pharma and medtech, Kuwait offers a well-funded market with high per-capita spending, growing oncology and chronic disease segments, and new manufacturing infrastructure. Companies should evaluate KDFA registration pathways, contract manufacturing opportunities, and the expanding private sector via DHAMAN.

For health tech and digital health, Kuwait's 27 hospitals awaiting digitization represent one of the GCC's largest remaining greenfield opportunities — backed by $56 million in government funding and clear institutional mandate.

Kuwait has the financial resources. Vision 2035 provides the strategic framework. The question for 2026 is whether the country can execute at the pace its ambitions demand — and for industry, whether they're positioned to be part of the build.